Related Experiment Videos
[The effect of calcium antagonists on the hemodynamic function in patients with heart failure]
Insights
Corinfar and phinoptin, calcium antagonists, effectively treat ischemic heart disease with chronic circulatory insufficiency. These drugs improve cardiac function and reduce vascular resistance in patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart disease (IHD) with chronic circulatory insufficiency (CCI) poses significant therapeutic challenges.
- Calcium antagonists are a class of drugs with potential applications in cardiovascular conditions.
Purpose of the Study:
- To evaluate the therapeutic efficacy of calcium antagonists, specifically corinfar and phinoptin, in patients suffering from IHD with CCI.
- To analyze the hemodynamic effects of corinfar and phinoptin in this patient cohort.
Main Methods:
- A study involving 48 patients diagnosed with ischemic heart disease and chronic circulatory insufficiency.
- Hemodynamic parameters were monitored to assess the impact of corinfar and phinoptin.
Main Results:
- Corinfar and phinoptin demonstrated a significant increase in cardiac contraction indices.
- A notable reduction in general peripheral resistance was observed.
- Simultaneous reduction in left ventricle volumes during both diastole and systole was recorded.
Conclusions:
- Corinfar and phinoptin are indicated for the treatment of patients with chronic circulatory insufficiency secondary to ischemic heart disease.
- The observed hemodynamic improvements support the use of these calcium antagonists in managing CCI.
Abstract:
The therapeutic effect of calcium antagonists corinfar and phinoptin was studied in 48 patients with ischemic heart disease with chronic circulatory insufficient (CCI). The hemodynamic effects of these calcium antagonists were characterized by an increase of indices of cardiac contraction and essential reduction of the general peripheral resistance with simultaneous reduction of the left ventricle volumes during diastole and systole. It is concluded that corinfar and phinoptin are indicated in patients with CCI.